The NSABP Study of Tamoxifen and Raloxifene (STAR) trial
- 10 January 2009
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 9 (1) , 51-60
Abstract
(2009). The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Review of Anticancer Therapy: Vol. 9, No. 1, pp. 51-60.Keywords
This publication has 36 references indexed in Scilit:
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialThe Lancet Oncology, 2008
- Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With HysterectomyJNCI: Journal of the National Cancer Institute, 2007
- Effect of Raloxifene on the Incidence of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Categorized by Breast Cancer RiskClinical Cancer Research, 2006
- The Science of Selective Estrogen Receptor Modulators: Concept to Clinical PracticeClinical Cancer Research, 2006
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJAMA, 2006
- Safety and Adverse Effects Associated With Raloxifene: Multiple Outcomes of Raloxifene EvaluationObstetrics & Gynecology, 2004
- Overview of the main outcomes in breast-cancer prevention trialsThe Lancet, 2003
- RaloxifeneDrugs, 2000
- Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal WomenNew England Journal of Medicine, 1997
- Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined AnnuallyJNCI: Journal of the National Cancer Institute, 1989